RARECast

A podcast by RARECast - Thursdays

Thursdays

Categories:

516 Episodes

  1. Determining If a Child's Neurologic or Psychiatric Symptoms are Caused by an Infection

    Published: 6/1/2016
  2. Making Genetic Data Accessible to Researchers

    Published: 5/25/2016
  3. How New Sequencing Technology Is Changing Our Understanding of Rare Diseases

    Published: 5/18/2016
  4. Marathon Readies DMD Drug for FDA

    Published: 5/11/2016
  5. Searching for Genes They May Protect Against Deadly Diseases

    Published: 5/4/2016
  6. Helping Patients with the Same Undiagnosed Genetic Condition Find Each Other

    Published: 4/27/2016
  7. Living with a Disease in Search of a Name

    Published: 4/20/2016
  8. New Means of Regulating Genes May Hold Promise for Rare Disease Patients

    Published: 4/13/2016
  9. Invitae Seeks a Faster, Cheaper Path to Diagnosing Genetic Diseases

    Published: 4/6/2016
  10. Filmmaker Turns Lens on the Rare Disease Community

    Published: 3/30/2016
  11. The Case for Keeping Orphans Where They Can Thrive

    Published: 3/23/2016
  12. Rare Disease Legislation Advancing at National, State Level

    Published: 3/16/2016
  13. The Evolving Relationship Between Patient Advocates and Pharma

    Published: 3/9/2016
  14. Phil Reilly on The Quest to Save Children with Rare Genetic Disorders

    Published: 3/2/2016
  15. Unlocking the Genetic Mysteries of Rare Diseases

    Published: 2/24/2016
  16. A Vision for Making Kansas City a Rare Disease Center of Excellence

    Published: 2/17/2016
  17. A Push in Canada for a National Rare Disease Strategy

    Published: 2/10/2016
  18. Jazzed in Utah for World Rare Disease Day

    Published: 2/3/2016
  19. Group Aims to Accelerate Repurposing of Drugs to Treat Rare Diseases

    Published: 1/27/2016
  20. Gene Therapies Bring New Hope to Rare Disease Patients

    Published: 1/20/2016

23 / 26

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.